| 2024 | A novel A2a adenosine receptor inhibitor effectively mitigates hepatic fibrosis in a metabolic dysfunction-associated steatohepatitis mouse model | 권영주; 류재상; 전경화; 서원효; 박서정 | Article |
| 2024 | Antioxidative Hyaluronic Acid-Bilirubin Nanomedicine Targeting Activated Hepatic Stellate Cells for Anti-Hepatic-Fibrosis Therapy | 권영주; 이용현; 박서정 | Article |
| 2025 | Cannabigerol attenuates liver fibrosis via AMPK activation: Regulation of lipid metabolism, inflammation, and hepatic stellate cell activation | 권영주; 전경화; 박서정; 박은선 | Article |
| 2023 | Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure–activity relationships | 권영주; 황수연; 박서정 | Article |
| 2022 | Discovery of (E)-3-(3-((2-Cyano-4' -dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis | 이화정; 김대기; 권영주; 최선; 박서정 | Article |
| 2024 | Exploring novel A2AAR antagonists: Design, synthesis, and evaluation of 2,6,9-trisubstituted purine derivatives as promising antifibrotic agents | 권영주; 류재상; 박서정 | Article |
| 2023 | Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers | 이화정; 권영주; 전경화; 황수연; 박서정 | Article |
| 2024 | Synthesis and biological assessment of chalcone and pyrazoline derivatives as novel inhibitor for ELF3-MED23 interaction | 권영주; 전경화; 황수연; 박서정; 조현지 | Article |
| 2023 | Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase II alpha catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells | 권영주; 박서정 | Article |
